Inimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026
Study demonstrated no dose-limiting toxicities and dose-responsive cytokine production consistent with TLR7/8 engagement Results support continued clinical development of INI-4001 as a potential monotherapy and in combination with other cancer treatments MISSOULA, Mont., Nov. 6, 2026...
Covered in this story
Call it yourself
No calls on $SITC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Site Centers Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.